Form 4: Vericel CMO Jonathan Hopper Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported the exercise of stock options and subsequent sale of 10,000 common shares, executed under a Rule 10b5-1 trading plan.

Summary

• Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp (VCEL), reported transactions on June 2, 2025, involving the company's common stock.
• Mr. Hopper exercised stock options to acquire 10,000 shares of common stock at an exercise price of $18.00 per share.
• Concurrently, he sold 10,000 shares of common stock at a price of $40.09 per share.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hopper on May 28, 2024.
• Following these transactions, Mr. Hopper's direct beneficial ownership of Vericel Corp common stock stands at 66,237 shares.
• He also retains 18,750 unexercised stock options, which originally represented the right to purchase 48,750 shares with the first vesting date on May 11, 2020, and an expiration date of February 11, 2030.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction (exercise and sell) conducted under a pre-arranged 10b5-1 plan, which is common practice and does not inherently indicate positive or negative company performance or outlook.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent transaction rather than an immediate reaction to market conditions, which can reduce concerns about opportunistic insider selling.
• The officer realized a significant profit by exercising options at $18.00 and selling the shares at $40.09, demonstrating personal financial benefit from the company's stock performance.

Negatives

• The Chief Medical Officer reduced his direct beneficial ownership of common stock by 10,000 shares, which some investors might interpret as a lack of confidence, although it was a pre-planned transaction.

Risks

• No specific risks are mentioned in this Form 4 filing. While insider selling can sometimes be misinterpreted by the market, this is not a direct risk stated in the document itself.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if pre-planned, might be viewed with slight caution by some investors, though it's a common practice for executives to monetize vested options. The transparency of the 10b5-1 plan mitigates potential negative interpretations.

Key Dates

Keywords

Vericel Corp, VCEL, Form 4, insider trading, stock option exercise, stock sale, Rule 10b5-1 plan, Jonathan Hopper, Chief Medical Officer, beneficial ownership